On behalf of the ASBMT Committee on Education, we are pleased to continue our monthly self-directed learning quiz "Basic Principles and Practices of Hematopoietic Cell Transplantation and Cell Therapy – Question and Answer Approach” for fellows in training, highlighting HCT and cell therapy topics. Answers to each question appear with evidence-based “non-exhaustive” peer-review commentary. Our aim is to provide you with a credible and freely available educational resource. Questions generated and reviewed by Syed Abutalib, MD, Mark R. Litzow, MD, and William A. Wood, MD.

Which of the following is the most consistent risk factor associated with progression of upper respiratory syncytial virus (RSV) respiratory tract infection to lower respiratory tract infection (RSV pneumonia) after hematopoietic cell transplantation?

Question Title

* 1. Which of the following is the most consistent risk factor associated with progression of upper respiratory syncytial virus (RSV) respiratory tract infection to lower respiratory tract infection (RSV pneumonia) after hematopoietic cell transplantation?

Which of the following statements about respiratory syncytial virus (RSV) infection and its treatment is correct?

Question Title

* 2. Which of the following statements about respiratory syncytial virus (RSV) infection and its treatment is correct?

Clinical cytomegalovirus (CMV) disease can be associated with which of the following problem(s)?

Question Title

* 3. Clinical cytomegalovirus (CMV) disease can be associated with which of the following problem(s)?

Which of the following statements about cytomegalovirus (CMV) seroconversion and infection is correct?

Question Title

* 4. Which of the following statements about cytomegalovirus (CMV) seroconversion and infection is correct?

Letermovir prophylaxis versus placebo for cytomegalovirus (CMV) in hematopoietic cell transplantation by Marty and colleagues published in New England Journal of Medicine:  Which of the following adverse effects was NOT observed in letermovir cohort?

Question Title

* 5. Letermovir prophylaxis versus placebo for cytomegalovirus (CMV) in hematopoietic cell transplantation by Marty and colleagues published in New England Journal of Medicine:  Which of the following adverse effects was NOT observed in letermovir cohort?

T